Cure8 research brief
The study suggests Aeromonas species are more frequently detected and at higher abundance in people with IBD versus non-IBD patients, and are associated with inflammatory markers — a finding that could point to a possible microbial contributor or marker of flares.
Adult patients with IBD, clinicians managing IBD flares, and researchers studying the gut microbiome and infection-related triggers for IBD activity.
The paper analyzed stool PCRs collected at a single center (Kangdong Sacred Heart Hospital) between June 2023 and May 2025. Aeromonas was the second most common pathogen detected in the IBD cohort and showed lower PCR cycle-thresholds (higher genetic material abundance) compared with non-IBD patients.
The authors conclude that Aeromonas positivity is more prevalent and linked to inflammation in IBD, but they caution that it remains unclear whether Aeromonas directly causes flares or is a consequence of already damaged mucosa.
The study is retrospective and based on PCR detection from stool; PCR positivity indicates bacterial genetic material but does not on its own prove active infection. Clinical context, symptoms, and other testing (culture, toxin assays, endoscopy) are important to interpret whether detection reflects pathogenic infection driving a flare.
Clinicians and researchers may consider Aeromonas as a potential microbial signal in IBD patients with worsening symptoms, but further prospective work is needed to determine causality and clinical management implications.
This is a single-center, retrospective PCR-based study. PCR detection indicates presence of bacterial genetic material but does not prove active infection. The authors explicitly note it is unclear whether Aeromonas is a cause of flares or a consequence of disrupted mucosa.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Wearable-derived digital biomarkers could enable earlier, less burdensome detection of IBD flares and better remote monitoring if they reliably predict mucosal inflammation.
Obese patients with FibroScan-detected steatosis in this cohort had a high frequency of colitis and some cases of IBD, dysplasia, and cancer, which could affect screening and symptom evaluation decisions.
The study suggests most adults with chronic diarrhea in this tertiary setting had organic/inflammatory disease and identifies accessible clinical and lab predictors that could help prioritize endoscopic evaluation.
